Molecular Partners AG Announces Underwritten Offering
Ticker: MOLN · Form: 6-K · Filed: Oct 28, 2024 · CIK: 1745114
Sentiment: neutral
Topics: offering, underwriting, capital-raise
TL;DR
Molecular Partners AG is doing a direct stock offering with Leerink and TD Securities.
AI Summary
On October 24, 2024, Molecular Partners AG entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for an underwritten registered direct offering. The filing does not specify the dollar amount or number of shares involved in this offering.
Why It Matters
This filing indicates Molecular Partners AG is raising capital through a direct offering, which could impact its financial position and future development plans.
Risk Assessment
Risk Level: medium — Underwritten offerings can signal a need for capital, potentially due to financial pressures or strategic investments, which carries inherent risk.
Key Players & Entities
- Molecular Partners AG (company) — Registrant and issuer of the offering
- Leerink Partners LLC (company) — Underwriter for the offering
- TD Securities (USA) LLC (company) — Underwriter for the offering
- October 24, 2024 (date) — Date of the underwriting agreement
FAQ
What is the purpose of the underwritten registered direct offering?
The filing states the offering is in connection with the issuance and sale by the Company, but does not specify the exact purpose or use of proceeds.
Who are the underwriters for this offering?
The underwriters are Leerink Partners LLC and TD Securities (USA) LLC, acting as representatives of the several underwriters named in the agreement.
When was the underwriting agreement entered into?
The underwriting agreement was entered into on October 24, 2024.
Does this filing specify the amount of capital being raised?
No, this filing does not specify the dollar amount or the number of shares to be issued in the offering.
Is Molecular Partners AG a foreign private issuer?
Yes, the form 6-K is a report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 886 words · 4 min read · ~3 pages · Grade level 13.9 · Accepted 2024-10-28 16:05:27
Key Financial Figures
- $5.49 — of the Company at an offering price of $5.49 per ADS. Gross proceeds from the Offeri
- $20 million — mpany, are expected to be approximately $20 million. The Offering was made pursuant to the
Filing Documents
- molecularpartners-offering.htm (6-K) — 24KB
- exhibit11-6xk.htm (EX-1.1) — 335KB
- exhibit31-6xk.htm (EX-3.1) — 496KB
- exhibit51-6xk.htm (EX-5.1) — 47KB
- exhibit991-6xk.htm (EX-99.1) — 12KB
- hlogo.jpg (GRAPHIC) — 28KB
- homburgerlogo.jpg (GRAPHIC) — 16KB
- molecularpartnerslogo1a.jpg (GRAPHIC) — 25KB
- 0001628280-24-043937.txt ( ) — 1010KB
Forward-Looking Statements
Forward-Looking Statements II-1 INCORPORATION BY REFERENCE This Report on Form 6-K, including the information contained in exhibits 1.1, 3.1, 5.1, 23.1 and 99.1 to this Report, shall be deemed to be incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-265960) and Form S-8 (File Nos. 333-272974 and 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 1.1 Underwriting Agreement, dated as of October 24, 2024, by and among the Company, Leerink Partners LLC and TD Securities (USA) LLC 3.1 Articles of Incorporation of the Company, as of October 25, 2024 (as currently in effect) 5.1 Opinion of Homburger AG 23.1 Consent of Homburger AG (included in exhibit 5.1) 99.1 Press release dated October 25, 2024 II-2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date October 28, 2024 s PATRICK AMSTUTZ Name Patrick Amstutz Title Chief Executive Officer II-3